1085841-38-8

Basic information

• Product Name: tert-Butyl 4-(5-nitropyridine-2-ylamino)piperidine-1-carboxylate
• Synonyms: tert-Butyl 4-(5-nitropyridine-2-ylamino)piperidine-1-carboxylate
• CAS NO: 1085841-38-8
• Molecular Formula: C15H22N4O4
• Molecular Weight: 322.35958
• Mol File: 1085841-38-8.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: tert-Butyl 4-(5-nitropyridine-2-ylamino)piperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl 4-(5-nitropyridine-2-ylamino)piperidine-1-carboxylate(1085841-38-8)
• EPA Substance Registry System: tert-Butyl 4-(5-nitropyridine-2-ylamino)piperidine-1-carboxylate(1085841-38-8)

Safety Data

• Hazardous Substances Data: 1085841-38-8(Hazardous Substances Data)

Upstream product

• 4487-59-6 2-bromo-5-nitropyridine 
• 87120-72-7 1-(tert-butoxycarbonyl)-4-aminopiperidine 
• 4548-45-2 2-chloro-5-nitropyridine 

Downstream Products

• 1404097-96-6 5-(4-(4-((5-nitropyridin-2-yl)amino)piperidine-1-carbonyl)-benzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione 

Relevant articles and documents

Synthesis and biological evaluation of 5-benzylidenepyrimidine-2,4,6(1H,3H, 5H)-trione derivatives for the treatment of obesity-related nonalcoholic fatty liver disease

Nonalcoholic fatty liver disease (NAFLD), one of chronic liver diseases, seems to be rising as the obesity epidemic continues. In this study, 54 novel (thio)barbituric acid derivatives have been synthesized and evaluated for pharmacological activity. 7h exhibited potent glucose-lowering effects on insulin-resistant HepG2 cells and regulated adiponectin and leptin expression in 3T3-L1 adipocytes. Oral administration of 7h at 25 mg kg-1 day -1 for 4 weeks improved the progression of high fat diet-induced NAFLD by reducing the weight of body, liver, and fat, as well as modulating serum levels of fasting glucose, insulin, triglycerides, LDL-c, ALT, adiponectin and hepatic contents of triglycerides, total cholesterol. H&E stainings revealed that 7h blocked fat deposition in liver and the increase of adipocyte number and size in adipose tissues from NAFLD. Furthermore, treatment with 7h alleviated the obese clinical symptoms, recovered serum biomarkers to appropriate ranges, and improved glucose tolerance by OGTT and IGTT in DIO mice.

KINASE INHIBITORS

The present invention provides kinase inhibitors of Formula (I). Wherein R1, R2, X and Z are as described herein, or a pharmaceutically acceptable salt thereof.